Covid-19 Impact on Heart Defect Closure Device Market, Global Research Reports 2020-2021

Heart defect closure devices are permanent implants designed to close defects between chambers of the heart or a patent ductus arteriosus. These are self-expandable, self-centering umbrella-like devices. The design and shape of the devices vary, as does their exact mode of deployment. They are implanted in the defect in a cardiac catheterization laboratory, through catheters inserted into either a vein or an artery (transcatheter or percutaneous approach). There are several types of defects, which include atrial septal defect (ASD), persistent patent ductus arteriosus (PDA), ventricular septal defect (VSD), patent foramen ovale (PFO), and left atrial appendage (LAA). Most of these defects are congenital, but can occur after a myocardial infarction or can be the result of a surgical repair of other congenital heart defects.
The classification of Heart Defect Closure Devices includes ASD Closure Devices, VSD Closure Devices, PDA Closure Devices, PFO Closure Devices and LAA Closure Devices. And the proportion of Amplatzer PFO Occluder in 2017 is about 33%, and the proportion is in decreasing trend from 2013 to 2017. LAA Closure Devices with the growth rate about 18%, in 2017 the market share is nearly 22%.
Heart Defect Closure Devices is widely used in hospitals and clinics. The most proportion of Heart Defect Closure Devices is used in Hospital, and the proportion in 2017 is 61%.
Europe is the largest consumption place, with a consumption market share nearly 30% in 2017. Following Europe, North America is the second largest consumption place with the consumption market share of 27%.

This report provides a complete quantitative data and qualitative analysis on the global market for Heart Defect Closure Device. Market size is analysed by country, product type, application, and competitors. Expanded coverage includes additional end-user industry breakdowns and in-depth producer profiles.
Prior to COVID-19, the global market for Heart Defect Closure Device was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of xx% during 2021–2026, whereas post-COVID-19 scenario, the market for Heart Defect Closure Device is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026.
This report covers market size and forecasts of Heart Defect Closure Device, including the following market information:
Global Heart Defect Closure Device Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
Global Heart Defect Closure Device Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
Global Heart Defect Closure Device Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
Global Heart Defect Closure Device Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K Units)

Key market players
Major competitors identified in this market include Abbott, Boston Scientific, LifeTech, Lepu Medical, Occlutech, W. L. Gore & Associates, Starway, CohereXMedical, Cardia, MicroPort, etc.

Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)

Based on the Type:
ASD Closure Devices
VSD Closure Devices
PDA Closure Devices
PFO Closure Devices
LAA Closure Devices

Based on the Application:
Hospitals
Clinics
Other